Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13MCash on Hand
3.6mo Cash Runway
Follow SNTI by emailGet an email when SNTI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SNTI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 10, 2026 ·
Financing Entered a $4.55 million equity commitment letter with CPIF II-9 Limited, an affiliate of Celadon Partners SPV 24 Limited, to buy common stock at the Nasdaq Minimum Price in quarterly settlements through December 31, 2027. Shares are sold unregistered, with a registration rights agreement to follow. Form 8-K · SEC filing
Oct 27, 2026 ·
Leadership Director Edward Mathers resigned from the Board and all its committees, effective immediately. The Board set October 30, 2026 as the record date for distribution of contingent value rights tied to the October 21, 2026 merger closing. Form 8-K · SEC filing
Oct 26, 2026 ·
Deal Senti completed its merger with ST NewCo, with Midco surviving as a wholly-owned Parent subsidiary and the Company divesting Midco and Opco. Holders receive one CVR per common share, with payments up to $60.0 million tied to SENTI-202 milestones. Form 8-K · SEC filing · Press release
Oct 15, 2026 ·
Deal Shareholders reconvened the 2026 annual meeting and approved the Merger Agreement with ST NewCo Limited, a reverse stock split of 1-for-20 to 1-for-50 at the Board's discretion, and Nasdaq 5635(d) approval for issuance above 19.99% upon exchange of Midco notes. Form 8-K · SEC filing
Oct 13, 2026 ·
Shareholder vote Senti Biosciences adjourned its October 8, 2026 annual meeting without conducting business to solicit more votes for the Merger Agreement Proposal. The meeting will reconvene October 15, 2026 at 8:00 a.m. Pacific time, with the record date unchanged at September 23, 2026. Form 8-K · SEC filing
Sep 24, 2026 ·
Leadership Director Brenda Cooperstone, Ph.D., resigned from the Board effective immediately, along with her roles as member and Chair of the Compensation Committee. The company said the resignation was not due to any disagreement on its operations, policies or practices. Form 8-K · SEC filing
Sep 24, 2026 ·
Financing Registers resale of up to 25,555,024 common shares issuable on exchange of senior secured convertible notes issued to two accredited investors, representing 82.1% of current outstanding common stock. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2026 · Phase 1 · Active Trial · SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS Registry primary completion date, not a results date
Apr 2024 · N/A · Results Expected · REMAP-WEST-FLARE - FLAg for Review Efficacy Investigation Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SNTI holds $13M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.9M/quarter from operations,
an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 4 months +40
ATM program on file since May 2026 +15
Shelf registration (S-3, Mar 2025) +10
Going-concern doubt in the latest 10-Q +15While such financing improved the Company’s liquidity, the Company concluded that substantial doubt continued to exist and that the Company’s cash and cash equivalents of $ 5.6 million as of September 30, 2026, were not sufficient for the Company to continue as a going concern for at least one year from the issuance…10-Q, Nov 2026
Share count +226% in a year +20
Raised after last reported balance sheet (Nov 2026) -10
Share count 85,706,263 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SNTI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNTI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.